FY2022 Q3 Financial and R&D Update
Revenue: Major Products in Japan
(Bn JPY)
coll
FY2021 Q3
FY2022 Q3
YOY
YTD Results
YTD Results
Lixiana
anticoagulant
70.5
79.5
+9.1
Tarlige
pain treatment
22.8
29.1
+6.3
Pralia
treatment for osteoporosis/ inhibitor of the progression of
bone erosion associated with rheumatoid arthritis
28.7
30.4
+1.7
Efient
antiplatelet agent
12.7
15.7
+3.0
Tenelia
type 2 diabetes mellitus treatment
18.6
17.0
-1.6
Vimpat
anti-epileptic agent
13.9
16.7
+2.8
treatment for bone complications caused by bone
Ranmark
15.6
15.6
-0.0
metastases from tumors
Canalia
type 2 diabetes mellitus treatment
13.0
12.5
-0.5
Loxonin
anti-inflammatory analgesic
17.6
14.7
-2.8
anti-cancer agent
Enhertu
6.9
8.5
+1.5
(HER2-directed antibody drug conjugate)
Emgality
prophylaxis of migraine attacks
3.4
4.7
+1.3
Daiichi-Sankyo
9View entire presentation